Zoledronate Can Be Given on the Same Day as the Last Teriparatide Dose
There is no need for a washout period when transitioning from teriparatide to zoledronate—you can administer zoledronate on the same day as the last teriparatide dose. The AACE/ACE guidelines explicitly state: "There is no apparent rationale for a 'washout period' or 'drug holiday' between the end of anabolic therapy and the initiation of antiresorptive treatment" 1.
Why Immediate Transition Is Recommended
The rationale for immediate sequential therapy is straightforward:
Bone loss occurs rapidly after stopping teriparatide. When teriparatide is discontinued, bone density declines quickly during the following year 1. This represents a critical window where bone gains can be lost.
Antiresorptive therapy prevents this loss. Use of bisphosphonates or denosumab after teriparatide prevents bone loss and may result in further increases in BMD 1.
Sequential therapy should be routine. Available data demonstrate that treatment with teriparatide should routinely be followed by antiresorptive therapy, typically with either a bisphosphonate or denosumab 1.
Evidence Supporting Same-Day Administration
Research actually suggests potential benefits to immediate or even concurrent administration:
A study demonstrated that a single dose of IV zoledronate given at the same time as starting teriparatide results in the most rapid increase in BMD at both lumbar spine and hip 1. While this addresses concurrent use rather than sequential, it demonstrates no pharmacologic incompatibility.
Recent data show that zoledronate administered sequential to teriparatide yields deeper and more prolonged bone resorption suppression than zoledronate alone 2, supporting the value of immediate transition.
Practical Implementation
On the day of transition:
- Administer the final teriparatide subcutaneous injection in the morning
- Schedule the zoledronate IV infusion for the same day (can be later that day)
- Ensure adequate hydration and renal function assessment before zoledronate (creatinine clearance >35 mL/min required) 1
- Consider pretreatment with acetaminophen or ibuprofen to reduce acute-phase reaction risk 3
Common Pitfall to Avoid
The main error is delaying the start of antiresorptive therapy based on an unfounded concern about drug interactions. Any gap between stopping teriparatide and starting zoledronate represents unnecessary risk of bone loss during a vulnerable period. The guideline evidence is clear that immediate transition is both safe and preferred 1.